226 related articles for article (PubMed ID: 29389078)
21. Dermal Safety of Tapinarof Cream 1%: Results From 4 Phase 1 Trials.
Jett J; McLaughlin M; Wilson T; Somerville M; DellaMaestra W; Rubenstein D; Piscitelli S
J Drugs Dermatol; 2022 Oct; 21(10):1084-1090. PubMed ID: 36219046
[TBL] [Abstract][Full Text] [Related]
22. Tapinarof cream for the topical treatment of plaque psoriasis in adults.
Prieto K; Duong JQ; Feldman SR
Expert Rev Clin Immunol; 2024 Apr; 20(4):327-337. PubMed ID: 38117596
[TBL] [Abstract][Full Text] [Related]
23. Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials.
Silverberg JI; Eichenfield LF; Hebert AA; Simpson EL; Stein Gold L; Bissonnette R; Papp KA; Browning J; Kwong P; Korman NJ; Brown PM; Rubenstein DS; Piscitelli SC; Somerville MC; Tallman AM; Kircik L
J Am Acad Dermatol; 2024 May; ():. PubMed ID: 38777187
[TBL] [Abstract][Full Text] [Related]
24. Occlusive treatment of chronic hand dermatitis with pimecrolimus cream 1% results in low systemic exposure, is well tolerated, safe, and effective. An open study.
Thaçi D; Steinmeyer K; Ebelin ME; Scott G; Kaufmann R
Dermatology; 2003; 207(1):37-42. PubMed ID: 12835546
[TBL] [Abstract][Full Text] [Related]
25. Tapinarof validates the aryl hydrocarbon receptor as a therapeutic target: A clinical review.
Silverberg JI; Boguniewicz M; Quintana FJ; Clark RA; Gross L; Hirano I; Tallman AM; Brown PM; Fredericks D; Rubenstein DS; McHale KA
J Allergy Clin Immunol; 2023 Dec; ():. PubMed ID: 38154665
[TBL] [Abstract][Full Text] [Related]
26. In situ biodistribution and residency of a topical anti-inflammatory using fluorescence lifetime imaging microscopy.
Alex A; Frey S; Angelene H; Neitzel CD; Li J; Bower AJ; Spillman DR; Marjanovic M; Chaney EJ; Medler JL; Lee W; Vasist Johnson LS; Boppart SA; Arp Z
Br J Dermatol; 2018 Dec; 179(6):1342-1350. PubMed ID: 29989149
[TBL] [Abstract][Full Text] [Related]
27. A Review of Topical Tapinarof for the Treatment of Plaque Psoriasis.
Grossmann MC; Pixley JN; Feldman SR
Ann Pharmacother; 2024 Jan; 58(1):76-85. PubMed ID: 37076998
[TBL] [Abstract][Full Text] [Related]
28. A randomized, double-blind, vehicle-controlled crossover study to determine the anti-pruritic efficacy, safety and local dermal tolerability of a topical formulation (srd174 cream) of the long-acting opiod antagonist nalmefene in subjects with atopic dermatitis.
Herzog JL; Solomon JA; Draelos Z; Fleischer A; Stough D; Wolf DI; Abramovits W; Werschler W; Green E; Duffy M; Rothaul A; Tansley R
J Drugs Dermatol; 2011 Aug; 10(8):853-60. PubMed ID: 21818506
[TBL] [Abstract][Full Text] [Related]
29. VTAMA
Gupta AK; Ravi SP; Vincent K; Abramovits W
Skinmed; 2022; 20(4):298-300. PubMed ID: 35976021
[TBL] [Abstract][Full Text] [Related]
30. Use of a dose-response model to guide future clinical trial of benvitimod cream to treat mild and moderate psoriasis.
Zang YN; Jiang DL; Cai L; Chen X; Wang Q; Xie ZW; Liu Y; Zhang CY; Jing S; Chen GH; Zhang JZ; Xu L; Feng WY; Zhao LB; Fang Y
Int J Clin Pharmacol Ther; 2016 Feb; 54(2):87-95. PubMed ID: 26709597
[TBL] [Abstract][Full Text] [Related]
31. Safety, efficacy, and dosage of 1% pimecrolimus cream for the treatment of atopic dermatitis in daily practice.
Lübbe J; Friedlander SF; Cribier B; Morren MA; García-Díez A; Gelmetti C; Hofmann H; Houwing RH; Kownacki S; Langley RG; Virtanen M; Wolff K; Wisseh S; McGeown C; Abrams B; Schneider D;
Am J Clin Dermatol; 2006; 7(2):121-31. PubMed ID: 16605292
[TBL] [Abstract][Full Text] [Related]
32. Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients.
Hanifin J; Gupta AK; Rajagopalan R
Br J Dermatol; 2002 Sep; 147(3):528-37. PubMed ID: 12207596
[TBL] [Abstract][Full Text] [Related]
33. Tapinarof for the treatment of psoriasis.
Nogueira S; Rodrigues MA; Vender R; Torres T
Dermatol Ther; 2022 Dec; 35(12):e15931. PubMed ID: 36226669
[TBL] [Abstract][Full Text] [Related]
34. Tapinarof Cream 1% Once Daily for the Treatment of Plaque Psoriasis: Case Photography of Clinical Outcomes from Three Phase 3 Trials.
Desai SR; Stein Gold L; Cameron MC; Golant A; Lewitt GM; Bruno MJ; Martin G; Brown PM; Rubenstein DS; Butners V; Tallman AM
Dermatol Ther (Heidelb); 2023 Oct; 13(10):2443-2460. PubMed ID: 37697121
[TBL] [Abstract][Full Text] [Related]
35. New topical drug development in atopic dermatitis: a place for hope.
Paul C
Br J Dermatol; 2012 Apr; 166(4):711. PubMed ID: 22452438
[No Abstract] [Full Text] [Related]
36. New Non-Steroidal Topical Therapies for Inflammatory Dermatoses-Part 2: Tapinarof.
DiRuggiero M; Mancuso-Stewart E; DiRuggiero D; Zirwas M
Skinmed; 2023; 21(3):177-181. PubMed ID: 37634099
[TBL] [Abstract][Full Text] [Related]
37. Crisaborole Topical Ointment, 2% in Adults With Atopic Dermatitis: A Phase 2a, Vehicle-Controlled, Proof-of-Concept Study.
Murrell DF; Gebauer K; Spelman L; Zane LT
J Drugs Dermatol; 2015 Oct; 14(10):1108-12. PubMed ID: 26461821
[TBL] [Abstract][Full Text] [Related]
38. Natural Compounds Tapinarof and
Tsuji G; Hashimoto-Hachiya A; Matsuda-Taniguchi T; Takai-Yumine A; Takemura M; Yan X; Furue M; Nakahara T
Front Immunol; 2022; 13():745997. PubMed ID: 35663970
[TBL] [Abstract][Full Text] [Related]
39. Spotlight on topical pimecrolimus in atopic dermatitis.
Wellington K; Jarvis B
Am J Clin Dermatol; 2002; 3(6):435-8. PubMed ID: 12113651
[TBL] [Abstract][Full Text] [Related]
40. Low systemic absorption and good tolerability of pimecrolimus, administered as 1% cream (Elidel) in infants with atopic dermatitis--a multicenter, 3-week, open-label study.
Staab D; Pariser D; Gottlieb AB; Kaufmann R; Eichenfield LF; Langley RG; Scott G; Ebelin ME; Barilla D; Schmidli H; Burtin P
Pediatr Dermatol; 2005; 22(5):465-71. PubMed ID: 16191004
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
